| 000 | 01915 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517192358.0 | ||
| 264 | 0 | _c20190503 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1552-4604 | ||
| 024 | 7 |
_a10.1002/jcph.1046 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBanfield, Christopher | |
| 245 | 0 | 0 |
_aThe Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _c04 2018 |
||
| 300 |
_a434-447 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aBlood Cell Count |
| 650 | 0 | 4 |
_aC-Reactive Protein _xanalysis |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPsoriasis _xblood |
| 650 | 0 | 4 |
_aPyrazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
| 650 | 0 | 4 |
_aTYK2 Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aScaramozza, Matthew | |
| 700 | 1 | _aZhang, Weidong | |
| 700 | 1 | _aKieras, Elizabeth | |
| 700 | 1 | _aPage, Karen M | |
| 700 | 1 | _aFensome, Andrew | |
| 700 | 1 | _aVincent, Michael | |
| 700 | 1 | _aDowty, Martin E | |
| 700 | 1 | _aGoteti, Kosalaram | |
| 700 | 1 | _aWinkle, Peter J | |
| 700 | 1 | _aPeeva, Elena | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 58 _gno. 4 _gp. 434-447 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jcph.1046 _zAvailable from publisher's website |
| 999 |
_c27913838 _d27913838 |
||